Asian safinamide deal with Meiji Seika a partial salve for Newron
This article was originally published in Scrip
An Asian licensing deal with Meiji Seika Pharma for the Parkinson's disease drug safinamide should give Newron Pharmaceuticals at least some breathing space after the double whammy it suffered last year.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.